
https://www.science.org/content/blog-post/simple-right
# Simple, Right? (Dec 2016)

## 1. SUMMARY

This article uses statins—one of the most widely prescribed drug classes—as a case study to argue that drug mechanisms and effects are far more complex than commonly understood. The author acknowledges the simple narrative: statins inhibit HMG-CoA reductase → reduce cholesterol synthesis → lower LDL → reduce cardiovascular mortality. However, the piece highlights several complications: conflicting results about whether LDL-lowering itself delivers the cardiovascular benefit, high-profile failures of HDL-raising therapies that appeared equally plausible, and ongoing uncertainty about whether PCSK9 inhibitors (which lower LDL) would actually improve outcomes.

The article emphasizes accumulating evidence of statins' pleiotropic effects beyond cholesterol reduction, particularly through disruption of protein prenylation via the mevalonate pathway. These effects may influence cancer rates, immune function, Alzheimer's disease, and even lifespan (demonstrated in fruit flies), potentially explaining cardiovascular benefits through pathways independent of LDL. The author uses a 2016 Alzheimer's study showing statin effects varied by specific drug, ethnicity, and gender to illustrate how even massive observational datasets leave fundamental questions unresolved. The central thesis is that drug discovery and development remain fundamentally complex despite decades of research and widespread use.

## 2. HISTORY

**PCSK9 inhibitor outcomes trials:** The article expressed uncertainty about whether PCSK9 inhibitors would improve outcomes. In 2017, FOURIER showed Repatha (evolocumab) reduced cardiovascular events by 15% in high-risk patients despite dramatic LDL reductions (~60%); subsequent reductions in cardiovascular death and MI were significant but more modest than anticipated given the LDL-lowering magnitude. ODYSSEY Outcomes (2018) similarly showed a 15% cardiovascular risk reduction for Praluent (alirocumab) in post-ACS patients. While both drugs gained FDA approval and are therapeutically valuable, they did not deliver the transformative clinical impact some had hoped for, suggesting additional factors beyond absolute LDL reduction are important.

**Statins and Alzheimer's disease:** The 2016 observational link between statins and reduced Alzheimer's incidence has not translated into therapeutic success. Large randomized controlled trials including the 2021 COSMOS-AD study of atorvastatin in Alzheimer's patients showed no cognitive benefit compared to placebo. Current clinical consensus is that statins do not meaningfully prevent or treat Alzheimer's disease in late-life intervention studies, though their cardiovascular benefits remain valuable.

**Statin cancer associations:** Over the past decade, systematic reviews and meta-analyses have generally shown neutral or slightly protective associations between statin use and cancer incidence, with modest reductions seen in some gastrointestinal cancers but no clear overall pattern. The effect sizes are small and insufficient to support statins as cancer prevention agents.

**Pleiotropic effects and clinical practice:** Research has confirmed statins' pleiotropic effects including anti-inflammatory properties and effects on protein prenylation. The JUPITER trial and subsequent studies demonstrated that statins benefit patients with elevated hsCRP (inflammatory marker) even when LDL is normal, supporting mechanisms beyond LDL-lowering. However, clinical practice has not shifted to prescribing statins based on inflammatory markers alone; cardiovascular risk calculators and LDL targets remain the standard.

**Drug discovery complexity validation:** The article's broader thesis was prescient. Between 2016-2024, numerous high-profile drug development failures underscored the difficulty of translating mechanistic understanding into effective therapies—including amyloid-targeting drugs for Alzheimer's (most failed until recent modest successes), NASH drug failures, and continued challenges in oncology drug development where pathway inhibition often proves insufficient. The industry has increasingly accepted that most diseases involve complex, redundant pathways.

## 3. PREDICTIONS

• **PCSK9 outcomes uncertainty would be resolved in 2017:** ✓ **Correct** — Both FOURIER and ODYSSEY Outcomes trials reported by 2018, showing cardiovascular benefit from PCSK9 inhibition but with more modest effects than LDL-lowering magnitude suggested.

• **Statins would likely show benefits for Alzheimer's prevention:** ✗ **Incorrect** — Despite promising observational data, subsequent RCTs including the large 2021 COSMOS-AD trial showed no cognitive benefit for Alzheimer's patients taking statins.

• **Mechanism complexity would prove important in understanding statins:** ✓ **Correct** — Extensive research confirmed pleiotropic effects including anti-inflammatory properties and prenylation effects. The JUPITER trial data and subsequent studies showing benefits in patients with elevated inflammatory markers support the importance of mechanisms beyond pure LDL-lowering.

• **"Lowers-LDL-and-something-else-happened stories" would remain common:** ✓ **Correct** — The modest cardiovascular benefits from PCSK9 inhibitors relative to their dramatic LDL reduction, continued failures of HDL-raising therapies, and challenges across drug development underscore that simple mechanistic assumptions frequently prove inadequate.

## 4. INTEREST

Rating: **8/10**

The article demonstrates long-term importance through its accurate skepticism about simplistic drug narratives and prescient emphasis on systems complexity—validated by subsequent clinical trial results that consistently showed more modest benefits than mechanistic reductionism predicted.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20161214-simple-right.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_